Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment‐naive patients with advanced EGFR mutation‐positive non‐small cell lung cancer: Protocol of an open‐label, single‐arm phase II trial

INTRODUCTION: Non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation has a higher incidence of brain metastases than wild‐type EGFR mutations. Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor (TKI), targets both EGFR‐TKI sensitizing and T790M‐resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Bora, Ji, Wonjun, Lee, Jae Cheol, Song, Si Yeol, Shin, Young Seob, Cho, Young Hyun, Park, Ji Eun, Park, Hyungjun, Choi, Chang‐Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396779/
https://www.ncbi.nlm.nih.gov/pubmed/37365915
http://dx.doi.org/10.1111/1759-7714.15018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396779/
https://www.ncbi.nlm.nih.gov/pubmed/37365915
http://dx.doi.org/10.1111/1759-7714.15018

Ejemplares similares